A pilot open-label trial of minocycline in patients with autism and regressive features
Open Access
- 8 April 2013
- journal article
- Published by Springer Nature in Journal of Neurodevelopmental Disorders
- Vol. 5 (1) , 9
Abstract
Minocycline is a tetracycline derivative that readily crosses the blood brain barrier and appears to have beneficial effects on neuroinflammation, microglial activation and neuroprotection in a variety of neurological disorders. Both microglial activation and neuroinflammation have been reported to be associated with autism. The study was designed to evaluate the effects of minocycline treatment on markers of neuroinflammation and autism symptomatology in children with autism and a history of developmental regression.Keywords
This publication has 45 references indexed in Scilit:
- Altered Balance of Proteolytic Isoforms of Pro-Brain-Derived Neurotrophic Factor in AutismJournal of Neuropathology & Experimental Neurology, 2012
- Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic StrokeStroke, 2011
- Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcomeBrain, Behavior, and Immunity, 2011
- Prospects for Minocycline NeuroprotectionArchives of Neurology, 2010
- Open-label add-on treatment trial of minocycline in fragile X syndromeBMC Neurology, 2010
- Chemokines and Chemokine Receptors: Standing at the Crossroads of Immunobiology and NeurobiologyImmunity, 2009
- Elevated immune response in the brain of autistic patientsJournal of Neuroimmunology, 2009
- Neuronal release of proBDNFNature Neuroscience, 2009
- A genetic variant that disrupts MET transcription is associated with autismProceedings of the National Academy of Sciences, 2006
- Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrationsProceedings of the National Academy of Sciences, 2006